Exhibit 99.1


                                                           FOR IMMEDIATE RELEASE

CONTACTS:
J. Thomas Parmeter
Chairman
(858) 558-6062
info@ppti.com


PROTEIN POLYMER TECHNOLOGIES SELECTS WILLIAM N. PLAMONDON III AS NEW CHIEF
EXECUTIVE OFFICER

        SAN DIEGO, April 11, 2005 -- Protein Polymer Technologies, Inc. (OTC BB:
PPTI) announced today the appointment of William N. Plamondon III as its new
Chief Executive Officer. J. Thomas Parmeter, PPTI's former CEO, will remain in
his capacity as Chairman of the Board of Directors, and Donald Kaplan, Ph.D.
will continue as President and Chief Operating Officer.

        "Bill Plamondon has been an advisor to PPTI for the last seven months
and was recently named to the Board of Directors. The addition of Bill to our
management team adds a very broad base of business experience to our
capabilities. Over the course of his career, Bill has served as CEO for several
public and private companies," said J. Thomas Parmeter, PPTI's Chairman. "His
skills and insight will add great value to PPTI's future."

        In his leadership roles, Mr. Plamondon has been the CEO of companies
exceeding $3 billion of revenue worldwide. He has successfully driven
acquisitions and reorganizations, in addition to building and growing businesses
in a variety of industries. Bill Plamondon is currently President and CEO of
R.I. Heller & Co., LLC, a management consulting firm, and serves on the Board of
Directors of several companies, charities and non-profit organizations.

        "I look forward to helping a great team of people with outstanding
scientific accomplishments continue to build a great company," Mr. Plamondon
said, following the announcement of his new role.

        Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes. From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices. These genetically engineered biomaterials are
high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements. Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants, scaffolds
for wound healing and tissue engineering, and depots for local drug delivery. To
date,







PPTI has been issued twenty-six U.S. Patents on its core technology with
corresponding issued and pending patents in key international markets.

        This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially from
those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up. The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, and
other recent filings with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain the risks associated
with the above statements.